EDP-235's coverage is so much greater than the (plasma adjusted) EC90 that is likely exceeds even EC95. However, measuring ECnn values higher than EC90 is subject to wide error bands and hence such values are generally not reported.
The short answer is that EDP-235 is very potent indeed against the SARS-CoV-2 variants tested. Moreover, since the SARS-CoV-2 protease is highly conserved across variants, EDP-235 should have strong potency against Omicron and any other variant.
I'm not clear on how to apply that to the quoted sentence.
I'm not quite clear on your question. They get the EC 90 for their drug from the cell based assay. They have to calculate what portion of their drug is free vs bound to protein. They then calculate trough levels of drug and want to achieve a trough level that is above the EC 90 for free drug which is the active component in vivo (a serum assay measures total - free plus protein bound). I guess they are aiming for some multiple above EC 90, bc you want a cushion - for variants that emerge that may have higher EC 90s, for patients that don't absorb as efficiently, food effects, missed doses, etc. The fact this is a finite short course of therapy probably gives the company more of a cushion to push the dose as well I may not have it 100%
Market Data 
Markets 
AI
